Compare SAR & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAR | PEPG |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.7M | 163.5M |
| IPO Year | 2006 | 2022 |
| Metric | SAR | PEPG |
|---|---|---|
| Price | $12.72 | $5.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $20.00 | $12.13 |
| AVG Volume (30 Days) | 133.8K | ★ 4.2M |
| Earning Date | 10-06-2026 | 11-10-2026 |
| Dividend Yield | ★ 23.79% | N/A |
| EPS Growth | 14.36 | ★ 25.61 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.78 | N/A |
| Revenue Next Year | $6.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.60 | $1.31 |
| 52 Week High | $24.07 | $7.80 |
| Indicator | SAR | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 29.42 | 84.04 |
| Support Level | N/A | $5.02 |
| Resistance Level | $14.27 | $5.37 |
| Average True Range (ATR) | 0.45 | 0.39 |
| MACD | 0.01 | 0.26 |
| Stochastic Oscillator | 13.97 | 72.25 |
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.